{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:45:06Z","timestamp":1787013906307,"version":"build-2736575974"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100010078","name":"Region Midtjylland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010078","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007606","name":"Aarhus Universitetshospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Drug\u2010related problems are important causes of patient harm and increased healthcare costs. To assist general practitioners in prioritizing patients in need of a critical medication review, we aimed to assess the ability of the Medication Risk Score (MERIS) to stratify patients with polypharmacy in general practice according to their risk of drug\u2010related problems. We conducted a cross\u2010sectional multi\u2010centre external validation study. Patients receiving more than five concomitant medications (polypharmacy) were eligible. The outcome was potentially serious drug\u2010related problems as evaluated by expert consensus. Performance was assessed in terms of calibration and discrimination indices. Of 497 patients, 489 were included in the main analysis. The median age (interquartile range) was 70.5\u2009years (60\u201379). In total, 372 potentially serious drug\u2010related problems were observed in 253 patients (52%). The MERIS was well calibrated above a score level of 10. The area under the receiver operating characteristic curve was 0.70 (95% confidence interval: 0.65\u20130.74). The performance of the MERIS was fair in patients with polypharmacy in general practice. Given the scale of drug\u2010related problems and the lack of efficient prioritization tools in this setting, the MERIS could be a useful risk indicator to complement usual practice.<\/jats:p>","DOI":"10.1111\/bcpt.13636","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T13:21:30Z","timestamp":1625750490000},"page":"319-331","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["External validation of the Medication Risk Score in polypharmacy patients in general practice: A tool for prioritizing patients at greatest risk of potential drug\u2010related problems"],"prefix":"10.1111","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-0548","authenticated-orcid":false,"given":"Kirsten","family":"H\u00f8j","sequence":"first","affiliation":[{"name":"Research Unit for General Practice  Aarhus Denmark"},{"name":"Department of Clinical Pharmacology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Schou","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Research Unit for General Practice  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sofie Baymler","family":"Lundberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Aarhus University Hospital  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flemming","family":"Bro","sequence":"additional","affiliation":[{"name":"Research Unit for General Practice  Aarhus Denmark"},{"name":"Department of Public Health Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Peter","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Aarhus University Hospital  Aarhus Denmark"},{"name":"Department of Biomedicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Aggerholm","family":"S\u00e6dder","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology Aarhus University Hospital  Aarhus Denmark"},{"name":"Department of Biomedicine Aarhus University  Aarhus Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200730050-00003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12995"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03628.x"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2015-004178"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4185"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaa057"},{"key":"e_1_2_8_8_1","unstructured":"World Health Organization.The third WHO global patient safety challenge: medication without harm.https:\/\/www.who.int\/patientsafety\/medication-safety\/en\/. Accessed March 16 2021."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-029477"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2225-3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-017-0621-2"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1984"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2017.06.002"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620933741"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0378-5"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04331.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0324"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2893"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12975"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2094"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13233"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13514"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.09.009"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.08.002"},{"issue":"64","key":"e_1_2_8_25_1","article-title":"Screening tools used by clinical pharmacists to identify elderly patients at risk of drug\u2010related problems on hospital admission: a systematic review","volume":"8","author":"Brady A","year":"2020","journal-title":"Pharmacy (Basel)"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.02.010"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12473"},{"key":"e_1_2_8_28_1","unstructured":"European Medicines Agency.Guideline on good pharmacovigilance practices (GVP). Module VI\u2014collection management and submission of reports of suspected adverse reactions to medicinal products (rev 2).https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. Accessed March 16 2021."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2012.02.110216"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14691"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7594"},{"key":"e_1_2_8_32_1","unstructured":"National Institute for Health and Care Excellence.Multimorbidity: clinical assessment and management. NICE guideline.2016.https:\/\/www.nice.org.uk\/guidance\/ng56. Accessed June 10 2021."},{"key":"e_1_2_8_33_1","unstructured":"Pharmaceutical Care Network Europe.The PCNE Classification V 9.0.https:\/\/www.pcne.org\/upload\/files\/334_PCNE_classification_V9-0.pdf. Accessed March 16 2021."},{"key":"e_1_2_8_34_1","unstructured":"World Health Organisation Collaborating Centre for Drug Statistics Methodology.ATC structure and principles.https:\/\/www.whocc.no\/atc\/structure_and_principles\/. Accessed March 16 2021."},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.7326\/M14-0698"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.02.005"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-020-01774-9"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1668-z"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61091-5"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/2042098620957142"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.2.260"},{"key":"e_1_2_8_42_1","first-page":"123","article-title":"Feasibility of a self\u2010administered survey to identify primary care patients at risk of medication\u2010related problems","volume":"7","author":"Makowsky MJ","year":"2014","journal-title":"J Multidiscip Healthc"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2015.03.140303"},{"key":"e_1_2_8_44_1","first-page":"A12190680","article-title":"Prevalence of polypharmacy in Denmark","volume":"67","author":"Kornholt J","year":"2020","journal-title":"Dan Med J"},{"key":"e_1_2_8_45_1","unstructured":"The Danish Pharmaceutical Association.[Danes redeem prescriptions for multiple drugs].2017.https:\/\/www.apotekerforeningen.dk\/\u2010\/media\/apotekerforeningen\/analysersundhed\/16112017\u2010danskere\u2010indloste\u2010recept\u2010paa\u2010flere\u2010forskellige\u2010lagemidler.pdf. Accessed March 16 2021."}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13636","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.13636","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.13636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T13:03:30Z","timestamp":1692968610000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.13636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/bcpt.13636"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.13636","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"2021-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}